Thomas Schall, ChemoCentryx CEO

Af­ter skep­ti­cism and tight vote at ad­comm, FDA ap­proves Chemo­Cen­tryx's rare dis­ease drug

Af­ter a tight ad­vi­so­ry com­mit­tee vote back in May that tilt­ed just slight­ly in fa­vor of ap­prov­ing Chemo­Cen­tryx’s ava­co­pan, the FDA has of­fi­cial­ly cleared the drug to treat a rare and se­ri­ous dis­ease known as an­ti-neu­trophil cy­to­plas­mic au­toan­ti­body (AN­CA)-vas­culi­tis.

The ap­proval makes ava­co­pan — now mar­ket­ed as Tavneos — the first new drug in a decade for AN­CA-as­so­ci­at­ed vas­culi­tis, ac­cord­ing to tri­al in­ves­ti­ga­tor Pe­ter Merkel.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.